Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT05277168
- Locations
- 🇺🇸
Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States
🇺🇸LSU Health Sciences Center, New Orleans, Louisiana, United States
🇦🇺Central Coast Local Health District, Gosford, New South Wales, Australia
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05273775
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Registration Number
- NCT05261646
A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 2000
- Registration Number
- NCT05254366
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05252546
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT05214976
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of SHR-1802 in Patients With Advanced Solid Tumor
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT05208177
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute&Hospital, Tianjin, Tianjin, China
To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 520
- Registration Number
- NCT05169801
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
A Trial of HR17031 Injection With Hepatic Insufficiency
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05151705
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05147259
© Copyright 2024. All Rights Reserved by MedPath